Latest Blog Posts Tagged "Industry"
August 02, 2018
Denali will move its drug into trials with patients with or without a LRRK2 mutation after new research points to potential widespread use of these therapies.
February 14, 2017
This study is a major step for PD research as it is the first drug trial where one's genetic information determines eligibility and is testing a potential therapy to slow or stop disease progression.
December 20, 2016
Herantis Pharma was awarded a $6M grant to study the safety and efficacy of a potential therapy for Parkinson's disease (PD): cerebral dopamine neurotrophic factor (CDNF).
November 10, 2016
The trial showed the therapy is safe and tolerable and that the drug gets into the central nervous system well and reduces levels of alpha-synuclein in blood serum. Phase II expected to begin in 2017.
September 07, 2016
Austrian biotech AFFiRiS reports a boost dose of its vaccine against key protein alpha-synuclein is safe and elicits antibodies. MJFF funded the trial.
August 25, 2016
With confidence from MJFF-led studies, Denali Therapeutics today announced it has licensed LRRK2 inhibitor compounds from Genentech.
April 14, 2016
MJFF's Dr. Brian Fiske discusses how we may be able to target treatments to the "type" of Parkinson's one has, much like is done in cancer care.
February 17, 2016
In our latest podcast, Dr. Ole Isacson, MD, PhD, a professor of neurology and neuroscience at Harvard Medical School, discusses stem cells and Parkinson's disease.
October 20, 2015
A research study reports improved symptoms and impact on Parkinson's disease biology with a cancer drug. See what an MJFF Scientific Advisory Board member has to say about these results.
October 12, 2015
MJFF CEO Todd Sherer, PhD, discusses therapies in human testing that have potential to slow or stop Parkinson's disease.